Janus Henderson Group PLC Has $5.35 Million Position in Keros Therapeutics, Inc. (NASDAQ:KROS)

Janus Henderson Group PLC grew its holdings in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 543.8% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 92,110 shares of the company's stock after acquiring an additional 77,803 shares during the quarter. Janus Henderson Group PLC owned 0.23% of Keros Therapeutics worth $5,354,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of KROS. FMR LLC lifted its position in Keros Therapeutics by 3.8% in the third quarter. FMR LLC now owns 4,899,134 shares of the company's stock worth $284,493,000 after purchasing an additional 179,374 shares during the period. Alkeon Capital Management LLC lifted its position in Keros Therapeutics by 18.7% in the third quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company's stock worth $110,194,000 after purchasing an additional 298,694 shares during the period. Darwin Global Management Ltd. lifted its position in Keros Therapeutics by 6.3% in the second quarter. Darwin Global Management Ltd. now owns 1,525,902 shares of the company's stock worth $68,772,000 after purchasing an additional 89,952 shares during the period. Holocene Advisors LP lifted its position in Keros Therapeutics by 22.5% in the third quarter. Holocene Advisors LP now owns 843,110 shares of the company's stock worth $48,959,000 after purchasing an additional 154,784 shares during the period. Finally, Nantahala Capital Management LLC lifted its position in Keros Therapeutics by 28.8% in the second quarter. Nantahala Capital Management LLC now owns 378,807 shares of the company's stock worth $17,311,000 after purchasing an additional 84,810 shares during the period. 71.56% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts recently commented on KROS shares. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Keros Therapeutics in a research report on Friday, November 22nd. Wedbush reiterated an "outperform" rating and set a $84.00 price objective on shares of Keros Therapeutics in a research note on Thursday, November 7th. HC Wainwright reiterated a "buy" rating and set a $100.00 price objective on shares of Keros Therapeutics in a research note on Thursday, November 7th. Scotiabank initiated coverage on Keros Therapeutics in a research note on Wednesday, October 16th. They set a "sector outperform" rating and a $77.00 price objective for the company. Finally, Bank of America dropped their price objective on Keros Therapeutics from $81.00 to $76.00 and set a "buy" rating for the company in a research note on Thursday, September 12th. Eleven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $93.25.

Keros Therapeutics Price Performance

Shares of NASDAQ:KROS traded down $0.83 during midday trading on Tuesday, reaching $66.31. The company's stock had a trading volume of 345,479 shares, compared to its average volume of 378,003. Keros Therapeutics, Inc. has a fifty-two week low of $27.31 and a fifty-two week high of $73.00. The company has a market capitalization of $2.69 billion, a P/E ratio of -12.96 and a beta of 1.20. The business's fifty day simple moving average is $60.50 and its 200-day simple moving average is $52.84.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($1.41) earnings per share for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The firm had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The company's revenue was up 4750.0% on a year-over-year basis. During the same period in the prior year, the company earned ($1.33) earnings per share. On average, analysts forecast that Keros Therapeutics, Inc. will post -5.26 earnings per share for the current fiscal year.

Keros Therapeutics Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.